Articles On Cyclopharm (ASX:CYC)
Title | Source | Codes | Date |
---|---|---|---|
Dr Boreham’s Crucible: Universal Biosensors chief John Sharman is exasperated about investor indifference
When your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he was exasperated about investor indifference towards the company. Indeed. In the spirit of Easter, one could say the stock indeed had been cruc... |
Stockhead | CYC | 2 weeks ago |
Dr Boreham’s Crucible
DR BOREHAM’S CRUCIBLE: UNIVERSAL BIOSENSORS By TIM BOREHAM When your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he was exasperated about investor indifference towards the company. Indeed. In the spi... |
Stockhead | CYC | 2 weeks ago |
Stocks of the Hour: Cyclopharm, lonic Rare Earths, Metals Acquisition
19 Mar 2024 - A snapshot of the stocks on the move, featuring Cyclopharm (ASX:CYC), lonic Rare Earths (ASX:IXR) and Metals Acquisition (ASX:MAC). |
FNN | CYC | 4 weeks ago |
Stocks of the Hour: Cyclopharm, lonic Rare Earths, Metals Acquisition
Cyclopharm (ASX:CYC) announced that its first USA Technegas clinical patients were imaged last week at two preeminent clinical sites located in St Louis, Missouri and Stanford, California. These landmark events follow US FDA approval of T... |
ShareCafe | CYC | 4 weeks ago |
Cyclopharm says milestone achieved with first US patients imaged with Technegas
The company said these events follow the US FDA approval of Technegas last October and the subsequent rollout of its plan for market penetration in medical facilities across the US. |
BiotechDispatch | CYC | 4 weeks ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | CYC | 1 month ago |
FNArena Corporate Results Monitor – 29-02-2024
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((4DX)) - 4DMedical ((APM)) - APM Human Services International ((AMI)) - Aurelia Metals ((ACL)) - Australian Clinical Labs ((AVG)) - Australian Vintage ((AVD)) - Avada Gro... |
FNArena | CYC | 1 month ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | CYC | 1 month ago |
Cyclopharm announces the appointment of new chief financial officer
Radiopharmaceutical company Cyclopharm (ASX:CYC) has announced the appointment of Jason Smith as its chief financial officer. |
BiotechDispatch | CYC | 2 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | CYC | 5 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | CYC | 5 months ago |
Why Fletcher Building, Navigator Global, Siteminder, and Skycity shares are dropping today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small decline. At the time of writing, the benchmark index is down 0.3% to 7,028.8 points. Four ASX shares that are falling more than most toda... |
Motley Fool | CYC | 6 months ago |
Can you guess which ASX 200 share is crashing 10% on Monday?
The Fletcher Building Ltd (ASX: FBU) share price has returned from its suspension and crashed deep into the red. In morning trade, the ASX 200 building materials company's shares are down 10% to $4.02. Why is this ASX 200 share crashing? I... |
Motley Fool | CYC | 6 months ago |
Dr Boreham’s Crucible: Dimerix has so far proved the doubters wrong. Next stop – the US
Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni... |
Stockhead | CYC | 6 months ago |
Experts say these ASX dividend stocks are top buys
The good news for income investors is that there are a lot of dividend stocks to choose from on the ASX. If you're paralysed by choice, don't worry! That's because listed below are a couple of ASX dividend shares that are highly recommende... |
Motley Fool | CYC | 6 months ago |
Dr Boreham’s Crucible: Cyclopharm
FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports. By Tim Boreham ASX code: ((CYC)) Share price: $2.57 Market cap: $270.4 million Shares on issue: 93,896,326 Chief executive officer: James McBrayer Board: D... |
FNArena | CYC | 6 months ago |
ScoPo’s Powerplays: ASX health stocks fall but Dimerix up 150% on drug licensing deal
ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag... |
Stockhead | CYC | 6 months ago |
Top brokers name 3 ASX shares to buy today
Many of Australia's top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Here's why they ar... |
Motley Fool | CYC | 6 months ago |
The record CSL dividend is being paid today. Here's the lowdown
Today is a good day to be a CSL Limited (ASX: CSL) shareholder. That's because later today the biotherapeutics company will be rewarding them with its biggest ever dividend. Payday for the CSL dividend In August, CSL released its FY 2023 r... |
Motley Fool | CYC | 6 months ago |
Analysts expect big juicy yields from these ASX dividend shares
If you want to boost your income portfolio this week, then it could be worth checking out the high-yield ASX dividend stocks listed below. Here's what analysts are saying about them: Charter Hall Group (ASX: CHC) The first ASX dividend sh... |
Motley Fool | CYC | 6 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) has just endured a horror day as investors scramble for the exits amid widespread fears over ASX sales. By the end of today's trading, the ASX 200 ha... |
Motley Fool | CYC | 6 months ago |
Leading brokers name 3 ASX shares to buy today
With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named... |
Motley Fool | CYC | 6 months ago |
Why CSL, Cyclopharm, Dicker Data, and Fletcher Building shares are pushing higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a sizeable decline. At the time of writing, the benchmark index is down 1.3% to 6,942.9 points. Four ASX shares that are not letting that holding them back ar... |
Motley Fool | CYC | 6 months ago |
Cyclopharm announces US approval for nuclear medicine imaging agent
The US FDA has approved Cyclopharm's (ASX:CYC) Technegas for the diagnosis and management of Pulmonary Embolism. |
BiotechDispatch | CYC | 6 months ago |
TMH Market Close: ASX200 drops a little in lead up to RBA’s Tuesday interest rates call
The ASX200 shed 0.2 of a per cent today as the market awaits the Reserve Bank’s interest rates decision tomorrow. Utilities was the best-performing sector today – up .6 of a per cent, while healthcare dropped 1.3 per cent. In the gree... |
themarketherald.com.au | CYC | 6 months ago |
In Case You Missed It: A maiden resource and high tech propeller deal
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today. ICYMI Leader... |
Stockhead | CYC | 6 months ago |
US regulator's approval a 'game-changer' for Cyclopharm
Sydney-based Cyclopharm is preparing to send hundreds of its generators to the US for use in diagnosing pulmonary embolisms after receiving regulatory approval. |
The West | CYC | 6 months ago |
Cyclopharm wins US FDA approval for Technegas
Cyclopharm (ASX:CYC) receives US FDA approval to commence commercial sales of its novel drug candidate, Technegas, in the US market Cyclopharm will provide and install Technegas generators in nuclear medicine departments to increase the... |
themarketherald.com.au | CYC | 6 months ago |
Market Highlights: ASX Futures down after a wild weekend in Washington, and 5 ASX small caps to watch today
Aussie Futures lower, but shares likely to show reilience RBA cash rate decision to be the main focus Markets expect central bank to hold rates steady at 4.1 per cent on Tuesday Futures for the benchmark ASX200 are trading 38 points l... |
Stockhead | CYC | 6 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | CYC | 6 months ago |
ASX cancer stocks guide: Here’s everything you need to know
According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W... |
Stockhead | CYC | 6 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | CYC | 7 months ago |
Energy stocks lead the market into positive territory
The US market closed slightly higher on Friday but overall finished the week lower as concerns resurfaced that the Federal Reserve may raise rates more than previously expected. Recent economic data, including lower-than-expected initial... |
ShareCafe | CYC | 7 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | CYC | 7 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | CYC | 7 months ago |
FNArena Corporate Results Monitor – 24-08-2023
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABY)) - Adore Beauty ((ASG)) - Autosports Group ((CHL)) - Camplify Holdings ((CWP)) - Cedar Woods Properties ((CGS)) - Cogstate ((CTD)) - Corporate Travel Management ((C... |
FNArena | CYC | 7 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | CYC | 8 months ago |
CLOSING BELL: CBA makes bank from rising rates, then issues a warning about mortgage arrears
Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in... |
Stockhead | CYC | 8 months ago |
ASX Health Stocks: Cyclopharm confident after US FDA inspection; Anteris a step closer to FDA approval
The US FDA has completed inspection of Cyclopharm’s facility Next Science says XPERIENCE reduces knee inflammation Anteris takes one step further toward receiving FDA approval Cyclopharm confident of FDA timeline after inspection Cyclop... |
Stockhead | CYC | 8 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | CYC | 8 months ago |
Closing Bell: ASX 200 trades flat on tepid start to week, but Mantle Minerals shines
ASX chopped about sideways, losing any slight semblance of fizz at close: -0.063% IT, Discretionary and Industrials led sectors, while Materials lagged The day’s clear winner was Mantle Minerals, up 50% at day’s end on further exploration... |
Stockhead | CYC | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | CYC | 9 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | CYC | 10 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | CYC | 10 months ago |
CRITERION: This ASX biotech is the sole dedicated player in a new $420 billion market
Joe Biden might have snubbed our leaders in favour of dealing with a wee $US31 trillion debt issue at home, but lung imaging house 4D Medical (ASX:4DX) still has 420 billion reasons to call POTUS a buddy. That’s because Congress has allocat... |
Stockhead | CYC | 10 months ago |
Dr Boreham’s Crucible: 30 years later, has Cyclopharm finally convinced the US FDA?
Many Aussie biotechs have endured a long wait to secure US Food and Drug Administration (FDA) approval for their drugs and devices, but Cyclopharm’s three-decade quest for the agency’s imprimatur surely sets the record. On September 29, 202... |
Stockhead | CYC | 11 months ago |
Cyclopharm confirms dates of US FDA facility inspection
Cyclopharm (ASX:CYC) has announced that it has been notified that the US FDA will inspect the company's Kinsgrove facility between late July and early August. |
BiotechDispatch | CYC | 11 months ago |
Market Highlights: Markets brace for more headwinds, and 5 ASX small caps to watch on Tuesday
The ASX will open flattish on Tuesday Crude prices rise another 2pc overnight The market awaits the Federal Budget later tonight The ASX is poised to open modestly higher on Tuesday after a flat session on Wall Street overnight. US trad... |
Stockhead | CYC | 11 months ago |
Weekly Ratings, Targets, Forecast Changes – 28-04-23
By Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquarie, Morgan Stanley, Morgans, Ord Minnett, Shaw and Partners and UBS. For the purpose of bro... |
FNArena | CYC | 11 months ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | CYC | 11 months ago |